Hepatitis C patients who have relapsed fare better when treated with the combined therapy of interferon and ribavirin for 12 months than when treated with interferon alone.
A team of French researchers studied 191 hepatitis C relapsers who were either treated with interferon alpha-2b plus ribavirin or interferon alpha-2b alone for one year. Their findings are reported in the August issue of Liver International.
The researchers found the virological sustained response rate was 61 percent for those treated with interferon alpha-2b plus ribavirin compared to 12 percent for those treated with interferon alpha-2b alone. They also noted a significant histological improvement in both treatment groups.
"The therapeutic schedule presented here can be considered of particular interest for the retreatment of relapsers," concluded the researchers.
Other sources: Liver Internatinal 2003 Aug;23(4):255-61